Denali's unique blood-brain barrier technology and strategic partnerships are significant competitive advantages in the neurodegenerative disease market. The company's strong cash position reduces the risk of needing immediate additional funding, supporting its R&D and commercialization efforts. This positions Denali well for potential growth, positively impacting its stock price.